No response to recombinant human erythropoietin therapy in patients with congenital dyserythropoietic anemia type I.
Congenital dyserythropoietic anemia (CDA) type I is a rare inherited bone marrow disorder characterized by moderate to severe macrocytic anemia with pathognomonic cytopathology of nucleated red blood cells. Previous studies have suggested that serum erythropoietin levels in affected patients are lower than expected for the degree of anemia. An earlier study demonstrated a substantial increase in the number of CFU-E in CDA type I pattern on addition of exogenous erythropoietin. The present study reports on the response to recombinant human erythropoietin in 8 patients with CDA type I. Eighteen weeks of treatment, starting at 300 IU/kg twice a week and gradually increasing to 500 IU/kg three times a week, did not have a substantial effect on the mean hemoglobin value. These results indicate that recombinant human erythropoietin (rHuEpo) is not beneficial to patients with CDA type I and that the relatively low levels of serum erythropoietin probably play no major role in the pathogenesis of the disease.
Tamary
H
H
Pediatric Hematology Oncology Center, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel.
Shalev
H
H
Pinsk
V
V
Zoldan
M
M
Zaizov
R
R
D000293:Adolescent; D000742:Anemia, Dyserythropoietic, Congenital / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011994:Recombinant Proteins; D017211:Treatment Failure
D011994:Recombinant Proteins; D004921:Erythropoietin